Free Trial
NASDAQ:CORT

Corcept Therapeutics (CORT) Stock Price, News & Analysis

Corcept Therapeutics logo
$69.72 +0.14 (+0.20%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$69.35 -0.37 (-0.53%)
As of 08/29/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Corcept Therapeutics Stock (NASDAQ:CORT)

Key Stats

Today's Range
$68.82
$69.88
50-Day Range
$67.17
$76.77
52-Week Range
$33.34
$117.33
Volume
397,600 shs
Average Volume
790,844 shs
Market Capitalization
$7.35 billion
P/E Ratio
61.70
Dividend Yield
N/A
Price Target
$134.50
Consensus Rating
Buy

Company Overview

Corcept Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
98th Percentile Overall Score

CORT MarketRank™: 

Corcept Therapeutics scored higher than 98% of companies evaluated by MarketBeat, and ranked 54th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Corcept Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Corcept Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Corcept Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Corcept Therapeutics are expected to grow by 36.03% in the coming year, from $1.36 to $1.85 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Corcept Therapeutics is 61.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.81.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Corcept Therapeutics is 61.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.19.

  • Price to Book Value per Share Ratio

    Corcept Therapeutics has a P/B Ratio of 11.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Corcept Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.85% of the float of Corcept Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Corcept Therapeutics has a short interest ratio ("days to cover") of 8.6.
  • Change versus previous month

    Short interest in Corcept Therapeutics has recently decreased by 1.52%, indicating that investor sentiment is improving.
  • Dividend Yield

    Corcept Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Corcept Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.85% of the float of Corcept Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Corcept Therapeutics has a short interest ratio ("days to cover") of 8.6.
  • Change versus previous month

    Short interest in Corcept Therapeutics has recently decreased by 1.52%, indicating that investor sentiment is improving.
  • News Sentiment

    Corcept Therapeutics has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Corcept Therapeutics this week, compared to 16 articles on an average week.
  • Search Interest

    14 people have searched for CORT on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,311,201.00 in company stock.

  • Percentage Held by Insiders

    20.80% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Corcept Therapeutics' insider trading history.
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CORT Stock News Headlines

How “Trump’s New Dollar” Could Impact Your Wealth
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."tc pixel
See More Headlines

CORT Stock Analysis - Frequently Asked Questions

Corcept Therapeutics' stock was trading at $50.39 at the start of the year. Since then, CORT stock has increased by 38.4% and is now trading at $69.72.

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings results on Thursday, July, 31st. The biotechnology company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.23 by $0.06. The business's revenue for the quarter was up 18.7% on a year-over-year basis.
Read the conference call transcript
.

Corcept Therapeutics' top institutional investors include Ingalls & Snyder LLC (7.28%), Parallel Advisors LLC (3.65%), State Street Corp (2.82%) and Geode Capital Management LLC (1.82%). Insiders that own company stock include Joseph K Belanoff, Hazel Hunt, Gary Charles Robb, Joseph Douglas Lyon, Sean Maduck, William Guyer, Daniel N Swisher, Jr and David L Mahoney.
View institutional ownership trends
.

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corcept Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Intel (INTC) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
7/31/2025
Today
8/30/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CORT
CIK
1088856
Employees
300
Year Founded
1998

Price Target and Rating

High Price Target
$145.00
Low Price Target
$121.00
Potential Upside/Downside
+92.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.13
Trailing P/E Ratio
61.70
Forward P/E Ratio
51.26
P/E Growth
N/A
Net Income
$141.21 million
Net Margins
18.51%
Pretax Margin
17.63%
Return on Equity
20.10%
Return on Assets
16.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.06
Quick Ratio
2.98

Sales & Book Value

Annual Sales
$675.04 million
Price / Sales
10.88
Cash Flow
$1.24 per share
Price / Cash Flow
56.03
Book Value
$6.03 per share
Price / Book
11.56

Miscellaneous

Outstanding Shares
105,370,000
Free Float
83,455,000
Market Cap
$7.35 billion
Optionable
Optionable
Beta
0.20

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:CORT) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners